Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Apomorphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 1.00 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 1.00 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | HPGD | P15428 | 6/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | PKM | P14618 | 4/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apomorphine SCHEMBL29414090 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| (S)Apomorphine SCHEMBL30554804 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| Apomorphine SCHEMBL29599870 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| Apomorphine SCHEMBL8541 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| Apomorphine SCHEMBL5605456 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| (S)Apomorphine SCHEMBL6922802 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| Apomorphine SCHEMBL1923763 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| Apomorphine SCHEMBL8524 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| Apomorphine SCHEMBL5904190 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| (S)Apomorphine SCHEMBL19469972 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| EP-3735988-B1 | SUBLINGUAL FILMS | SUMITOMO PHARMA AMERICA INC (US) | 2026-02-04 | — | — | EP | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| EP-3746138-B1 | ELECTRICAL CONDENSATION AEROSOL DEVICE | ALEXZA PHARMACEUTICALS INC (US) | 2025-12-10 | — | — | EP | claimed |
| EP-3442516-B1 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | UNIV CANBERRA (AU) | 2025-11-12 | — | — | EP | claimed |
| EP-4154885-B1 | APOMORPHINE-CONTAINING PERCUTANEOUS ABSORPTION TYPE PREPARATION | MEDRX CO LTD (JP) | 2025-08-06 | — | — | EP | claimed |
| US-20250235641-A1 | DEVICE TO DELIVER A PREDETERMINED AMOUNT OF A SUBSTANCE TO A NATURAL ORIFICE OF THE BODY | APTARGROUP INC. (US) | 2025-07-24 | — | — | US | claimed |
| EP-3426327-B1 | NEEDLELESS INJECTION DEVICE EQUIPPED WITH AN IMPROVED INJECTION NOZZLE | CROSSJECT (FR) | 2025-07-09 | — | — | EP | claimed |
| CN-112047848-B | Dopamine D 2 Receptor selective agonists and uses thereof | 中国科学院分子细胞科学卓越创新中心 | 2023-05-02 | — | — | CN | claimed |
| EP-3174526-B2 | COMPOSITION CONTAINING APOMORPHINE AND A DIVALENT METAL CATION | BRITANNIA PHARMACEUTICALS LTD (GB) | 2023-03-22 | — | — | EP | claimed |
| EP-3151837-B1 | PROTECTIVE EFFECT OF DMPC, DMPG, DMPC/DMPG, EGPG, LYSOPG AND LYSOPC AGAINST DRUGS THAT CAUSE CHANNELOPATHIES | SIGNPATH PHARMA INC (US) | 2023-03-15 | — | — | EP | claimed |
| US-20220409830-A1 | DEVICE TO DELIVER A PREDETERMINED AMOUNT OF A SUBSTANCE TO A NATURAL ORIFICE OF THE BODY | SIPNOSE LTD. (IL) | 2022-12-29 | — | — | US | claimed |
| EP-1765303-B2 | ORAL TABLET SAFEGUARDED AGAINST ABUSE | GRUENENTHAL GMBH (DE) | 2022-11-23 | — | — | EP | claimed |
| WO-2022195044-A1 | ROLLED ORAL THIN FILMS HAVING A HIGH LEVEL OF ACTIVE-INGREDIENT LOADING | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2022-09-22 | — | — | WO | claimed |
| EP-3385252-B1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2022-09-21 | — | — | EP | claimed |
| US-20220193101-A1 | Methods for treating and Pharmaceutical compositions | BOEHRINGER INGELHEIM INT (DE) | 2022-06-23 | — | — | US | claimed |
| WO-2022102709-A1 | MICRONEEDLE ARRAY COATED WITH COMPOSITION CONTAINING PARTICLES | 株式会社 メドレックス | 2022-05-19 | — | — | WO | claimed |
| EP-3294278-B1 | APOMORPHINE FOR THE TREATMENT OF METHYLPHENIDATE INDUCED HYPERACTIVITY | 4P PHARMA (FR) | 2022-05-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193101-A1 | Methods for treating and Pharmaceutical compositions | PDE5A, SLC5A1, SLC5A2 | DRD2 2800/4885DRD4 2891/4885DRD3 2992/4885 |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | TNF, PYCARD, VAPA | DRD2 656/4885DRD4 2138/4885DRD3 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.